246 related articles for article (PubMed ID: 26633561)
1. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
[TBL] [Abstract][Full Text] [Related]
2. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
3. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
[TBL] [Abstract][Full Text] [Related]
4. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
5. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
[TBL] [Abstract][Full Text] [Related]
6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
7. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
8. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
[TBL] [Abstract][Full Text] [Related]
12. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
13. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of folate vitamers in patients with a newly diagnosed prostate cancer or hyperplasia.
Awwad HM; Ohlmann CH; Stoeckle M; Geisel J; Obeid R
Clin Biochem; 2018 Jun; 56():41-46. PubMed ID: 29673813
[TBL] [Abstract][Full Text] [Related]
19. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA.
Macoska JA; Begley LA; Dunn RL; Siddiqui J; Wei JT; Sarma AV
Prostate; 2008 Mar; 68(4):442-52. PubMed ID: 18196514
[TBL] [Abstract][Full Text] [Related]
20. CC chemokine ligand 18 and IGF-binding protein 6 as potential serum biomarkers for prostate cancer.
Xu Y; Zhang L; Sun SK; Zhang X
Tohoku J Exp Med; 2014 May; 233(1):25-31. PubMed ID: 24747338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]